We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Diagnostic Test for Blood Volume Analysis

By LabMedica International staff writers
Posted on 27 May 2022
Print article
Image: BVA-100 is the first FDA-cleared diagnostic blood test for quantification of blood volume status (Photo courtesy of Daxor Corporation)
Image: BVA-100 is the first FDA-cleared diagnostic blood test for quantification of blood volume status (Photo courtesy of Daxor Corporation)

Implantable left ventricular assist devices have dramatically changed the face of advanced heart failure treatment and constitute a USD 350 million annual market in the US. Patients suffering from persistent blood volume derangements have lower survival and decreased with left ventricular assist device (LVAD) functionality but go largely undiagnosed. Accurate quantification of total blood volume, plasma volume, and red blood cell volume analysis can inform physicians, leading to better treatment strategies and better patient outcomes. Now, the first diagnostic blood test cleared by the FDA provides safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms.

Daxor Corporation’s (Oak Ridge, TN, USA) BVA-100 (Blood Volume Analyzer) provides clinicians with accurate, actionable data to optimize treatment plans and individualize care improving outcomes and reducing duration and cost of care. It directly quantifies the intravascular blood, plasma and red cell giving actionable information needed to achieve optimal fluid management. The BVA-100 quantifies circulating blood volume utilizing the gold standard methodology, the indicator tracer dilution technique. The test is administered at the bedside, blood samples are drawn and sent to the laboratory for processing. Preliminary data is available within 30 minutes to help guide decisions in emergency situations.

Over 100 published peer-reviewed studies across many medical conditions have proven the BVA-100’s unique safety, accuracy, efficacy, and value. New data has validated the benefits of BVA-100 in improving survival for advanced heart failure patients with LVAD. The study describes variations in blood volume status (total blood and red blood cell volume) in 45 stable ambulatory patients with LVAD. Blood volume parameters were measured with the BVA-100 diagnostic blood test, which is a safe, 98% accurate, and objective test to directly quantify blood volume and composition. The study concluded that plasma volume abnormality was found in 75% of patients. The data revealed that only 9% of these patients had normal blood volume results; 54% had significant red blood cell deficit and 12% had red blood cell excess.

“This research reinforces that a volume-guided approach in treating advanced heart failure with the BVA-100 blood test is paramount in informing the correct treatment strategies - resulting in significantly better clinical benefits and survival for patients,” said Michael Feldschuh, President, and CEO of Daxor Corporation.

Related Links:
Daxor Corporation 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more